Previous 10 | Next 10 |
2023-11-02 15:15:04 ET Intra-Cellular Therapies, Inc. (ITCI) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Juan Sanchez – Head-Investor Relations Sharon Mates – Chairman and Chief Executive Officer Mark Neumann ...
2023-11-02 07:45:01 ET More on Intra-Cellular Therapies Intra-Cellular Therapies: Caplyta's Rise And A Promising Pipeline Intra-Cellular Therapies Q3 2023 Earnings Preview Seeking Alpha’s Quant Rating on Intra-Cellular Therapies Historical earnings dat...
Q3 2023 total revenues increased to $126.2 million , compared to $71.9 million in the same period in 2022 CAPLYTA Q3 2023 net product sales were $125.8 million , compared to $71.9 million for the same period in 2022...
Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...
Intra-Cellular Therapies Inc. (ITCI) is expected to report $-0.59 for Q3 2023
2023-11-01 13:12:50 ET More on Intra-Cellular Therapies Intra-Cellular Therapies: Caplyta's Rise And A Promising Pipeline Intra-Cellular Therapies, Inc. (ITCI) Q2 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Intra-Cellular Therapies Hi...
NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will participate in two upcoming investor con...
NEW YORK, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced it will host a conference call and live webcast ...
2023-10-16 08:30:08 ET PCTEL ( NASDAQ: PCTI ) +48% . Essa Pharma ( EPIX ) +32% . Almacenes Exito ( EXTO ) +32% . Ambrx Biopharma ( AMAM ) +32% Provides Safety and Efficacy Data from Ongoing Phase 1/2 APEX-01 Trial of ARX5...
NEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will present at the 2023 Cantor Fitzgerald G...
News, Short Squeeze, Breakout and More Instantly...
Intra-Cellular Therapies Inc. Company Name:
ITCI Stock Symbol:
NASDAQ Market:
Intra-Cellular Therapies Inc. Website:
2024-06-20 15:00:05 ET Graig Suvannavejh from Mizuho Securities issued a price target of $100.00 for ITCI on 2024-06-20 12:10:00. The adjusted price target was set to $100.00. At the time of the announcement, ITCI was trading at $76.06. The overall price target consensus...
In Study 502, lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints Lumateperone 42 mg met the primary endpoint of change from baseline at Week 6 on the Montgomery- Åsberg Depression Rating Sc...
NEW YORK, June 10, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Office...